🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementAnyone else get weird vivid dreams on sema??

Anyone else get weird vivid dreams on sema??

SleepFixSam Thu, Apr 2, 2026 at 1:51 AM 5 replies 590 viewsPage 1 of 1
SleepFixSam
Member
212
678
Nov 2024
Hawaii
Apr 2, 2026 at 1:51 AM#1

Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

What I am after is whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out.

Tell me what I have not thought of.

2 22pete_nash, hank_denver
Reply Quote Save Share Report
Dr.AddMedPHL
Senior Member
1,234
6,234
Mar 2024
Philadelphia, PA
Apr 2, 2026 at 2:23 AM#2

This one has a reasonably settled answer, so here it is. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

1 21sarah_nash92
Reply Quote Save Share Report
hannah_MT
New Member
23
89
Feb 2026
Bozeman, MT
Apr 2, 2026 at 2:55 AM#3
Dr.AddMedPHL said:
Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts.

Agreed on adaptation, with a caveat: adaptation applies to gastric emptying and not to everything. If your problem is the aversion rather than the fullness, waiting does less, because the aversion is central and it is the mechanism working as intended.

50 20MaxMetOK, MounjBrad, nick_newbie and 47 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Apr 2, 2026 at 3:28 AM#4
SleepFixSam said:
Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

Same position here, arrived at the long way round. The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

49 19MeganSA_TX, LarryQC_SD, wanda_boise and 46 others
Reply Quote Save Share Report
rachel_ABQ
Member
178
890
Dec 2024
Albuquerque, NM
Apr 2, 2026 at 6:28 AM#5

From the other side of the consultation, briefly. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.

Last edited: Apr 2, 2026 at 11:28 AM
48 18Dr.CardioMD, EndoResFellow, PharmacoVig_BOS and 45 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register